SCHEMBL5119971

SCHEMBL5119971

CC1CC(c2cccc(Br)c2)=CCN1C(=O)c1cc2ncc(Cl)cn2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 9/20 0.39
ALDH1A1 P00352 5/20 0.39
POLB P06746 5/20 0.39
ESR2 Q92731 4/20 0.39
ESR1 P03372 2/20 0.39
TDP1 Q9NUW8 6/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 3/20 0.37
LMNA P02545 2/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TSHR P16473 1/20 0.37
KDM4E B2RXH2 3/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NR4A1 P22736 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4789880 0.92 TDP1 (0.47) GRM5ALDH1A1POLBESR2ESR1
SCHEMBL4790271 0.92 NPC1 (0.41) GRM5ALDH1A1HPGDLMNARAB9A
SCHEMBL4755882 0.91 GRM5 (0.42) GRM5ALDH1A1POLBESR2ESR1
SCHEMBL4789179 0.90 GRM5 (0.43) GRM5ALDH1A1POLBESR2ESR1
SCHEMBL4756503 0.90 GRM5 (0.44) GRM5ALDH1A1POLBESR2ESR1
SCHEMBL4790148 0.90 ALDH1A1 (0.42) GRM5ALDH1A1POLBESR2ESR1
SCHEMBL4790035 0.90 TDP1 (0.45) GRM5ALDH1A1POLBESR2ESR1
SCHEMBL4790002 0.87 HPGD (0.43) GRM5ALDH1A1POLBESR2ESR1
SCHEMBL4790072 0.87 GRM5 (0.44) GRM5ALDH1A1ESR2TDP1GAA
SCHEMBL4789891 0.87 GRM5 (0.40) GRM5ALDH1A1MAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032998-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-07 US claimed
WO-2008015271-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-07 WO disclosed
US-20080032998-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-07 US disclosed
US-20080032998-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-07 US disclosed
US-20080032998-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032998-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine GRM5, GRM1, GRIK5 GRM5 1/4885ALDH1A1 2588/4885POLB 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.